Sangamo Therapeutics, Inc. (NASDAQ:SGMO) has been able to make several great advancements regarding its pipeline in the past year. The most notable program advancement would be regarding the fact that the company caught a huge surprise development from the FDA relating to its Fabry Disease treatment program. That is, it was noted by the U.S. agency that it would be able to file a Biologics License Application [BLA] of isaralgagene civaparvovec for the treatment of patients with Fabry Disease [FD] under an A ...